Biologics to boost Biocon business over the next 3 years, say analysts

Biologics accounted for 27% of total revenue in FY19

Analysts expect biologics business to help biopharma major Biocon post double-digit growth in both revenue and net profit over the next three financial years. 

Biocon’s current biosimilars pipeline through its own and partner launches has potential to generate $377 million in revenue from the US and Europe in 2020-21, they say. During the 12 months ended March 31, 2019, biologics revenue doubled to Rs 1,517 crore from a year before.

Kiran Mazumdar-Shaw, chairperson and managing director, had said in a recent earnings call: “Our biosimilars strategy has begun to deliver, with the start of monetisation of the pipeline in the developed markets